Woodline Partners’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.1M | Buy |
837,199
+541,989
| +184% | +$11.7M | 0.1% | 309 |
|
|
2025
Q1 | $4.9M | Buy |
295,210
+268,445
| +1,003% | +$4.46M | 0.03% | 515 |
|
|
2024
Q4 | $491K | Buy |
+26,765
| New | +$491K | ﹤0.01% | 835 |
|
|
2024
Q1 | – | Sell |
-474,159
| Closed | -$14.8M | – | 527 |
|
|
2023
Q4 | $14.8M | Buy |
+474,159
| New | +$14.8M | 0.16% | 185 |
|
|
2023
Q3 | – | Sell |
-830,355
| Closed | -$19.9M | – | 581 |
|
|
2023
Q2 | $19.9M | Buy |
830,355
+399,450
| +93% | +$9.57M | 0.24% | 126 |
|
|
2023
Q1 | $8.11M | Buy |
+430,905
| New | +$8.11M | 0.11% | 226 |
|
|
2022
Q4 | – | Sell |
-395,549
| Closed | -$6.47M | – | 744 |
|
|
2022
Q3 | $6.47M | Buy |
395,549
+135,582
| +52% | +$2.22M | 0.09% | 252 |
|
|
2022
Q2 | $3.66M | Buy |
+259,967
| New | +$3.66M | 0.06% | 303 |
|
|
2022
Q1 | – | Sell |
-416,200
| Closed | -$9.71M | – | 710 |
|
|
2021
Q4 | $9.71M | Sell |
416,200
-172,659
| -29% | -$4.03M | 0.14% | 203 |
|
|
2021
Q3 | $9.78M | Sell |
588,859
-74,195
| -11% | -$1.23M | 0.16% | 164 |
|
|
2021
Q2 | $16.2M | Buy |
663,054
+272,463
| +70% | +$6.65M | 0.3% | 88 |
|
|
2021
Q1 | $10.1M | Buy |
390,591
+339,678
| +667% | +$8.76M | 0.22% | 116 |
|
|
2020
Q4 | $2.72M | Sell |
50,913
-276,502
| -84% | -$14.8M | 0.07% | 184 |
|
|
2020
Q3 | $13.5M | Buy |
327,415
+265,840
| +432% | +$11M | 0.44% | 68 |
|
|
2020
Q2 | $2.99M | Buy |
+61,575
| New | +$2.99M | 0.12% | 128 |
|